CN111337674A - 一种用于预测心血管事件风险的试剂盒 - Google Patents
一种用于预测心血管事件风险的试剂盒 Download PDFInfo
- Publication number
- CN111337674A CN111337674A CN201811549833.8A CN201811549833A CN111337674A CN 111337674 A CN111337674 A CN 111337674A CN 201811549833 A CN201811549833 A CN 201811549833A CN 111337674 A CN111337674 A CN 111337674A
- Authority
- CN
- China
- Prior art keywords
- paraoxonase
- activity
- kit
- tris
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000007211 cardiovascular event Effects 0.000 title claims abstract description 23
- 102000006996 Aryldialkylphosphatase Human genes 0.000 claims abstract description 42
- 108010008184 Aryldialkylphosphatase Proteins 0.000 claims abstract description 42
- 230000000694 effects Effects 0.000 claims abstract description 41
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 8
- 239000000758 substrate Substances 0.000 claims description 36
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 29
- 239000007853 buffer solution Substances 0.000 claims description 27
- 239000000872 buffer Substances 0.000 claims description 25
- 239000012190 activator Substances 0.000 claims description 19
- 239000000243 solution Substances 0.000 claims description 19
- YBADLXQNJCMBKR-UHFFFAOYSA-N (4-nitrophenyl)acetic acid Chemical group OC(=O)CC1=CC=C([N+]([O-])=O)C=C1 YBADLXQNJCMBKR-UHFFFAOYSA-N 0.000 claims description 14
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical group [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 12
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 abstract description 24
- 102000004895 Lipoproteins Human genes 0.000 abstract description 10
- 108090001030 Lipoproteins Proteins 0.000 abstract description 10
- 238000001727 in vivo Methods 0.000 abstract description 7
- 239000003963 antioxidant agent Substances 0.000 abstract description 6
- 230000003078 antioxidant effect Effects 0.000 abstract description 6
- 230000003647 oxidation Effects 0.000 abstract description 4
- 238000007254 oxidation reaction Methods 0.000 abstract description 4
- 238000012216 screening Methods 0.000 abstract description 3
- 238000006243 chemical reaction Methods 0.000 description 25
- 230000008859 change Effects 0.000 description 16
- 238000002835 absorbance Methods 0.000 description 12
- 208000029078 coronary artery disease Diseases 0.000 description 10
- 238000001514 detection method Methods 0.000 description 8
- 230000036632 reaction speed Effects 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 239000007983 Tris buffer Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- WYMSBXTXOHUIGT-UHFFFAOYSA-N paraoxon Chemical compound CCOP(=O)(OCC)OC1=CC=C([N+]([O-])=O)C=C1 WYMSBXTXOHUIGT-UHFFFAOYSA-N 0.000 description 5
- 229960004623 paraoxon Drugs 0.000 description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 229940049953 phenylacetate Drugs 0.000 description 4
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000008033 biological extinction Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000035484 reaction time Effects 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- YKYOUMDCQGMQQO-UHFFFAOYSA-L Cadmium chloride Inorganic materials Cl[Cd]Cl YKYOUMDCQGMQQO-UHFFFAOYSA-L 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229910021592 Copper(II) chloride Inorganic materials 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 1
- 230000014155 detection of activity Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- -1 pH8.5 Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
- G01N21/33—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using ultraviolet light
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Hematology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Plasma & Fusion (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811549833.8A CN111337674A (zh) | 2018-12-18 | 2018-12-18 | 一种用于预测心血管事件风险的试剂盒 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811549833.8A CN111337674A (zh) | 2018-12-18 | 2018-12-18 | 一种用于预测心血管事件风险的试剂盒 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111337674A true CN111337674A (zh) | 2020-06-26 |
Family
ID=71181344
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811549833.8A Pending CN111337674A (zh) | 2018-12-18 | 2018-12-18 | 一种用于预测心血管事件风险的试剂盒 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111337674A (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090208992A1 (en) * | 2008-02-20 | 2009-08-20 | The Cleveland Clinic Foundation | Paraoxonase 1 enzymatic activity, a risk indicator for major adverse cardiovascular events |
CN102027127A (zh) * | 2008-03-14 | 2011-04-20 | 生物融合技术株式会社 | 一种包括肝羧酸酯酶1的用于诊断肝癌的血浆生物标记物工具及肝癌筛选方法 |
CN103233061A (zh) * | 2013-04-30 | 2013-08-07 | 王连升 | Pon-1活性检测试剂盒及其检测方法 |
-
2018
- 2018-12-18 CN CN201811549833.8A patent/CN111337674A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090208992A1 (en) * | 2008-02-20 | 2009-08-20 | The Cleveland Clinic Foundation | Paraoxonase 1 enzymatic activity, a risk indicator for major adverse cardiovascular events |
CN102027127A (zh) * | 2008-03-14 | 2011-04-20 | 生物融合技术株式会社 | 一种包括肝羧酸酯酶1的用于诊断肝癌的血浆生物标记物工具及肝癌筛选方法 |
CN103233061A (zh) * | 2013-04-30 | 2013-08-07 | 王连升 | Pon-1活性检测试剂盒及其检测方法 |
Non-Patent Citations (2)
Title |
---|
JOSE J CERON等: "Serum paraoxonase 1 (PON1) measurement: an update" * |
R. F. MUELLER等: "Plasma Paraoxonase Polymorphism: A New Enzyme Assay, Population, Family, Biochemical, and Linkage Studies" * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Goth | A simple method for determination of serum catalase activity and revision of reference range | |
Ricart-Jane et al. | Anticoagulants and other preanalytical factors interfere in plasma nitrate/nitrite quantification by the Griess method | |
KR20140096280A (ko) | 혈액 샘플 분석 방법 | |
WO2003106981A1 (en) | "an improved optical sensor and method for measuring concentration of a chemical constituent using its intrinsic optical absorbance" | |
Grillo et al. | Improved method for determination of high-density-lipoprotein cholesterol II. Enzymic determination of cholesterol in high-density lipoprotein fractions with a sensitive reagent. | |
CN110088628B (zh) | 对样品中干扰物的确定 | |
Jelikić-Stankov et al. | Determination of uric acid in human serum by an enzymatic method using N-methyl-N-(4-aminophenyl)-3-methoxyaniline reagent | |
JPS584918B2 (ja) | グルタメ−ト−オキザロアセテ−ト−トランスアミナ−ゼ及びグルタメ−ト−ピルベ−ト−トランスアミナ−ゼの測定法 | |
CA2798920C (en) | Detection of nicotine metabolites | |
GB2250819A (en) | Myocardial infarction test | |
CN111337674A (zh) | 一种用于预测心血管事件风险的试剂盒 | |
Inada et al. | Faster determination of clottable fibrinogen in human plasma: an improved method and kinetic study. | |
Deeg et al. | Kinetic determination of serum glucose by use of the hexokinase/glucose-6-phosphate dehydrogenase method | |
Guirguis et al. | 175 Years of Bilirubin Testing: Ready for Point‐of‐Care? | |
CN105628636B (zh) | 一种糜蛋白酶活力检测方法 | |
JP2516381B2 (ja) | 過酸化水素の定量方法及びその定量用試薬 | |
JP4577863B2 (ja) | カルシウムイオン測定用組成物および測定方法 | |
Wong et al. | Quantification of plasma hemoglobin in the presence of bilirubin with bilirubin oxidase | |
JP3713901B2 (ja) | 破骨細胞由来酸性ホスファターゼの測定方法 | |
US4454230A (en) | Assay method and reagent composition for the determination of magnesium | |
JP2001231595A (ja) | 特異的破骨細胞由来酸性ホスファターゼの測定方法 | |
JP4647742B2 (ja) | アスコルビン酸の分析方法及び分析用試薬 | |
CN102901711A (zh) | 定量检测肌氨酸的肌氨酸氧化酶方法及检测试剂盒 | |
JPH0772157A (ja) | 糖化蛋白の定量方法およびその定量用キット | |
RU2786591C2 (ru) | Способ определения показателей коагуляции плазмы крови - активности тромбина, времени рекальцификации плазмы и толерантности плазмы к гепарину |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20220311 Address after: 201318 floor 2, building 2, No. 638, Jianyun Road, Pudong New Area, Shanghai Applicant after: SHANGHAI YUANKE INDUSTRIAL DEVELOPMENT CO.,LTD. Address before: 201500 block D, room 112, building 13, No. 51, Wan'an street, Zhujing Town, Jinshan District, Shanghai Applicant before: Shanghai substrate Biochemical Technology Co.,Ltd. |
|
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Zhang Jianhua Inventor after: Shi Yiming Inventor before: Zhang Jianhua |
|
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200626 |